Form 8-K

8-K — AIM ImmunoTech Inc.

Accession: 0001493152-26-042196

Filed: 2026-09-10

Period: 2026-09-03

CIK: 0000946644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Entry into a Material Definitive Agreement

Item: Unregistered Sales of Equity Securities

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.1 (ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000946644

2026-09-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 3, 2026

AIM

IMMUNOTECH INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-27072

52-0845822

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2117

SW Highway 484, Ocala, Florida

34473

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (352) 448-7797

Not

Applicable

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

AIM

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01

Entry

into a Material Definitive Agreement.

September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of two exchange agreements

(the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together, the “Partitioned

Promissory Notes”) with Streeterville Capital, LLC (the “Lender”) related to that certain Promissory Note dated November

18, 2025 (the “Promissory Note”). Pursuant to the Exchange Agreements and Partitioned Promissory Notes, the Company and the

Lender converted approximately $450,000 of the Promissory Note into 1,921,441 shares (the “Exchange Shares”) of the Company’s

common stock, at an average conversion price of approximately $0.234 per share.

The

Company’s stockholders previously approved the conversion or other satisfaction of the Promissory Note, pursuant to NYSE American

Company Guide Sections 713(a) and 713(b), at a special meeting of stockholders held on July 15, 2026.

The

foregoing descriptions of the Exchange Agreements and Partitioned Promissory Notes are qualified in their entirety by reference to the

full text of the form of the Exchange Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

Item

3.02

Unregistered

Sales of Equity Securities.

The

information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

The

Exchange Shares were or will be issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as

amended, provided by Section 3(a)(9) thereof as securities exchanged by the Company with its existing security holder exclusively where

no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange.

Item

9.01

Financial

Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

10.1

Form of Exchange Agreement.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

September 10, 2026

AIM ImmunoTech Inc.

By:

/s/

Thomas K. Equels

Thomas

K. Equels

Chief

Executive Officer

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit

10.1

THE

EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED.

EXCHANGE

AGREEMENT

This

Exchange Agreement (this “Agreement”) is entered into as of September ____, 2026 by and between Streeterville Capital,

LLC, a Utah limited liability company (“Lender”), and AIM ImmunoTech, Inc., a Delaware corporation (“Borrower”).

Capitalized terms used in this Agreement without definition shall have the meanings given to them in the Original Note (defined below).

Borrower previously sold and issued to Lender that certain Promissory Note dated November 18, 2025 in the original principal amount of

$3,301,250.00 (the “Original Note”) pursuant to that certain Note Purchase Agreement dated November 18, 2025 by and

between Lender and Borrower (the “Purchase Agreement,” and together with the Original Note and all other documents

entered into in conjunction therewith, the “Transaction Documents”).

Subject to the terms of this Agreement, Borrower and Lender desire to partition a new Promissory Note in the original principal amount

of $________ (the “Partitioned Note”) from the Original Note and then cause the outstanding balance of the Original

Note to be reduced by an amount equal to the initial outstanding balance of the Partitioned Note.

Borrower and Lender further desire to exchange (such exchange is referred to as the “Note Exchange”) the Partitioned

Note for the delivery of ________ shares of the Company’s Common Stock, par value $0.001 (the “Common Stock,”

and such ________ shares of Common Stock, the “Exchange Shares”), according to the terms and conditions of this Agreement.

The Note Exchange will consist of Lender surrendering the Partitioned Note in exchange for the Exchange Shares, which will be issued

free of any restrictive securities legend pursuant to Rule 144. Other than the surrender of the Partitioned Note, no consideration of

any kind whatsoever shall be given by Lender to Borrower in connection with this Agreement.

Lender and Borrower now desire to exchange the Partitioned Note for the Exchange Shares on the terms and conditions set forth herein.

NOW,

THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Recitals and Definitions. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this Agreement

are true and accurate, are contractual in nature, and are hereby incorporated into and made a part of this Agreement.

Partition. Effective as of the date hereof, Borrower and Lender agree that the Partitioned Note is hereby partitioned from the

Original Note. Following such partition of the Original Note, Borrower and Lender agree that the Original Note shall remain in full force

and effect, provided that the outstanding balance of the Original Note shall be reduced by an amount equal to the initial outstanding

balance of the Partitioned Note.

Issuance of Shares. Pursuant to the terms and conditions of this Agreement, the Exchange Shares shall be delivered to Lender on

or before September ____, 2026 and the Note Exchange shall occur with Lender surrendering the Partitioned Note to Borrower on the Free

Trading Date (as defined below). On the Free Trading Date, the Partitioned Note shall be cancelled and all obligations of Borrower under

the Partitioned Note shall be deemed fulfilled. All Exchange Shares delivered hereunder shall be delivered via DWAC to Lender’s

designated brokerage account. Subject to the securities laws and regulations, Borrower agrees to provide all necessary cooperation or

assistance that may be required to cause all Exchange Shares delivered hereunder to become Free Trading (the first date such occurs,

the “Free Trading Date”). For purposes hereof, the term “Free Trading” means that (a) the Exchange

Shares have been cleared and approved for public resale by the compliance departments of Lender’s brokerage firm and the clearing

firm servicing such brokerage, and (b) such shares are held in the name of the clearing firm servicing Lender’s brokerage firm

and have been deposited into such clearing firm’s account for the benefit of Lender.

Closing. The closing of the transaction contemplated hereby (the “Closing”) along with the delivery of the

Exchange Shares to Lender shall occur on the date that is mutually agreed to by Borrower and Lender by means of the exchange by email

of .pdf documents, but shall be deemed to have occurred at the offices of Capital Law Partners PLLC in Lehi, Utah.

Holding Period, Tacking and Legal Opinion. Lender and Borrower agree that for the purposes of Rule 144 (“Rule 144”)

of the Securities Act of 1933, as amended (the “Securities Act”), the holding period of the Partitioned Note and the

Exchange Shares will include Lender’s holding period of the Original Note from November 18, 2025, which date is the date that the

Original Note was originally issued. Borrower agrees not to take a position contrary to this Section 5 in any document, statement, setting,

or situation. Borrower agrees to take all action necessary to issue the Exchange Shares without restriction, and not containing any restrictive

legend without the need for any action by Lender; provided that the applicable holding period has been met. In furtherance thereof, prior

to the Closing, counsel to Lender may, in its sole discretion, provide an opinion that: (a) the Exchange Shares may be resold pursuant

to Rule 144 without volume or manner-of-sale restrictions or current public information requirements; and (b) the transactions contemplated

hereby and all other documents associated with this transaction comport with the requirements of Section 3(a)(9) of the Securities Act.

Borrower represents that it is in full compliance with the tests and standards set forth in Rule 144(i)(2) as of the date of this Agreement.

The Exchange Shares are being issued in substitution of and exchange for and not in satisfaction of the Partitioned Note. The Exchange

Shares shall not constitute a novation or satisfaction and accord of the Partitioned Note. Borrower acknowledges and understands that

the representations and agreements of Borrower in this Section 5 are a material inducement to Lender’s decision to consummate the

transactions contemplated herein.

Representations, Warranties and Agreements of Borrower. In order to induce Lender to enter into this Agreement, Borrower, for

itself, and for its affiliates, successors and assigns, hereby acknowledges,

represents, warrants and agrees as follows: (a) Borrower has full power and authority to enter into this Agreement and to incur and perform

all obligations and covenants contained herein, all of which have been duly authorized by all proper and necessary action, (b) no consent,

approval, filing or registration with or notice to any governmental authority is required as a condition to the validity of this Agreement

or the performance of any of the obligations of Borrower hereunder, (c) except as specifically set forth herein, nothing herein shall

in any manner release, lessen, modify or otherwise affect Borrower’s obligations under the Original Note, (d) the issuance of the

Exchange Shares is duly authorized by all necessary corporate action and the Exchange Shares are validly issued, fully paid and non-assessable,

free and clear of all taxes, liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any

kind, nature and description, (e) Borrower has not received any consideration in any form whatsoever for entering into this Agreement,

other than the surrender of the Partitioned Note, and (f) Borrower has taken no action which would give rise to any claim by any person

for a brokerage commission, placement agent or finder’s fee or other similar payment by Borrower related to this Agreement.

Representations, Warranties and Agreements of Lender. In order to induce Borrower to enter into this Agreement, Lender, for itself,

and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a) Lender has full

power and authority to enter into this Agreement and to incur and perform all obligations and covenants contained herein, all of which

have been duly authorized by all proper and necessary action, and (b) no consent, approval, filing or registration with or notice to

any governmental authority is required as a condition to the validity of this Agreement or the performance of any of the obligations

of Lender hereunder.

Arbitration. By its execution of this Agreement, each party agrees to be bound by the Arbitration Provisions (as defined in the

Purchase Agreement) set forth as an exhibit to the Purchase Agreement and the parties agree to submit all Claims (as defined in the Purchase

Agreement) arising under this Agreement or any Transaction Document or other agreement between the parties and their affiliates to binding

arbitration pursuant to the Arbitration Provisions.

Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction,

validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State of Utah, without giving

effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdictions) that would

cause the application of the laws of any jurisdictions other than the State of Utah. The provisions set forth in the Purchase Agreement

to determine the proper venue for any disputes are incorporated herein by this reference. BORROWER HEREBY IRREVOCABLY WAIVES ANY RIGHT

IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING

OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

10.

Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if all signing parties had

signed the same document. All counterparts shall be construed together and constitute the same instrument. The exchange of copies of

this Agreement and of signature pages by facsimile transmission or other

electronic transmission (including email) shall constitute effective execution and delivery of this Agreement as to the parties and may

be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile transmission or other

electronic transmission (including email) shall be deemed to be their original signatures for all purposes.

11.

Attorneys’ Fees. In the event of any arbitration or action at law or in equity to enforce or interpret the terms of this

Agreement, the prevailing party shall therefore be entitled to an additional award of the full amount of the attorneys’ fees and

expenses paid by such prevailing party in connection with the arbitration, litigation and/or dispute without reduction or apportionment

based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrator’s

or a court’s power to award fees and expenses for frivolous or bad faith pleading.

12.

No Reliance. Each party acknowledges and agrees that neither the other party nor any of such other party’s officers, directors,

members, managers, equity holders, representatives or agents has made any representations or warranties to the party or any of its agents,

representatives, officers, directors, or employees except as expressly set forth in this Agreement and the Transaction Documents and,

in making its decision to enter into the transactions contemplated by this Agreement, the party is not relying on any representation,

warranty, covenant or promise of the other party or such other party’s officers, directors, members, managers, equity holders,

agents or representatives other than as set forth in this Agreement.

13.

Severability. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve

the objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect.

14.

Entire Agreement. This Agreement, together with the Transaction Documents, and all other documents referred to herein, supersedes

all other prior oral or written agreements between Borrower, Lender, its affiliates and persons acting on its behalf with respect to

the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding of the parties

with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Lender nor Borrower

makes any representation, warranty, covenant or undertaking with respect to such matters.

15.

Amendments. This Agreement may be amended, modified, or supplemented only by written agreement of the parties. No provision of

this Agreement may be waived except in writing signed by the party against whom such waiver is sought to be enforced.

16.

Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors

and assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Lender hereunder

may be assigned by Lender to a third party, including its financing sources, in whole or in part. Neither party shall assign this Agreement

or any of its obligations herein without the prior written consent of the other party.

17.

Continuing Enforceability; Conflict Between Documents. Except as otherwise modified by this Agreement, the Original Note and each

of the other Transaction Documents shall remain in full force and effect, enforceable in accordance with all of its original terms and

provisions. This Agreement shall not be effective or binding unless and until it is fully executed and delivered by Lender and Borrower.

If there is any conflict between the terms of this Agreement, on the one hand, and the Original Note or any other Transaction Document,

on the other hand, the terms of this Agreement shall prevail.

18.

Time of Essence. Time is of the essence with respect to each and every provision of this Agreement.

19.

Notices. Unless otherwise specifically provided for herein, all notices, demands or requests required or permitted under this

Agreement to be given to Borrower or Lender shall be given as set forth in the “Notices” section of the Purchase Agreement.

20.

Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things, and shall

execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in

order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

[Remainder

of page intentionally left blank]

WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set forth above.

COMPANY:

AIM IMMUNOTECH, INC.

By:

Name:

Title:

LENDER:

STREETERVILLE CAPITAL, LLC

By:

John M. Fife, President

[Signature

Page to Exchange Agreement]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Sep. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 03, 2026

Entity File Number

001-27072

Entity Registrant Name

AIM

IMMUNOTECH INC.

Entity Central Index Key

0000946644

Entity Tax Identification Number

52-0845822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2117

SW Highway 484

Entity Address, City or Town

Ocala

Entity Address, State or Province

Entity Address, Postal Zip Code

34473

City Area Code

(352)

Local Phone Number

448-7797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

AIM

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration